[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"paclitaxel-induced-peripheral-neuropathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:paclitaxel-induced-peripheral-neuropathy":81},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,68,96,123],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100636959","a-single-arm-prospective-study-of-papaverine-for-the-treatment-of-refractory-peripheral-neuropathy-induced-by-taxane-based-chemotherapy-100636959",false,"NCT07572461","A Single-Arm, Prospective Study of Papaverine for the Treatment of Refractory Peripheral Neuropathy Induced by Taxane-Based Chemotherapy","Inclusion Criteria:\n\n* Age 18 to 75 years.\n* Histologically or cytologically confirmed malignancy.\n* Prior treatment with a taxane-containing chemotherapy regimen, including but not limited to paclitaxel, docetaxel, or nab-paclitaxel, with completion of chemotherapy at least 4 weeks before enrollment.\n* Persistent, clinically significant peripheral neuropathy mainly attributed to taxane-based chemotherapy, with NCI-CTCAE v5.0 sensory neuropathy grade ≥ 2.\n* Failure of at least one standard treatment for chemotherapy-induced peripheral neuropathy, such as duloxetine ≥ 60 mg\u002Fday, pregabalin ≥ 150 mg\u002Fday, or gabapentin ≥ 900 mg\u002Fday, for at least 4 weeks, defined as lack of symptom improvement or intolerance to treatment.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n* Adequate organ function, including hematologic, hepatic, and renal function within acceptable ranges.\n* Willingness to participate and ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Peripheral neuropathy due to causes other than chemotherapy, such as uncontrolled diabetes mellitus (HbA1c \\> 7.0%), severe renal insufficiency, vitamin B12 deficiency, thyroid dysfunction, or history of alcohol abuse.\n* Known hypersensitivity to papaverine or any of its components.\n* Contraindications to papaverine, such as complete atrioventricular block.\n* Current use of other investigational drugs that may affect neurological function.\n* Pregnant or breastfeeding women.\n* Severe hepatic or renal dysfunction, defined as ALT or AST \\> 3 × upper limit of normal or serum creatinine \\> 2 × upper limit of normal.\n* Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in the study.","ALL","18 Years","75 Years",{"count":19,"type":20},43,"ESTIMATED","INTERVENTIONAL",[23],"NA","Chemotherapy-induced peripheral neuropathy (CIPN) is a common and often long-lasting side effect of cancer treatment. Patients may experience numbness, tingling, pain, burning sensations, weakness, or difficulty with walking and daily activities. Paclitaxel-related CIPN is especially common, and current treatment options are limited. For patients whose symptoms do not improve with standard therapies such as duloxetine, pregabalin, or gabapentin, there is an important unmet clinical need. Papaverine is a vasodilator and smooth muscle relaxant that may improve blood flow in the small vessels supplying nerves. Based on the hypothesis that impaired microcirculation and ischemia may contribute to CIPN, papaverine may help relieve symptoms and support nerve recovery. Preliminary clinical observations by the investigators suggested that papaverine injection may rapidly improve numbness and weakness in some patients with refractory paclitaxel-induced CIPN.This is a prospective, single-center, single-arm, open-label phase II study designed to evaluate the preliminary efficacy and safety of papaverine injection in patients with refractory paclitaxel-induced peripheral neuropathy. Eligible participants are adults aged 18 to 75 years with histologically or cytologically confirmed malignancy, prior treatment with a paclitaxel-containing regimen, persistent clinically significant neuropathy of grade 2 or higher, and failure of at least one standard treatment for CIPN. Participants will receive papaverine hydrochloride 120 mg diluted in 100 mL normal saline by intravenous infusion once daily, given as 1 treatment day followed by 6 rest days, with 7 days defined as one cycle. Up to 3 cycles of treatment may be given if patients benefit and tolerate therapy well.The main goal of the study is to assess improvement in patient-reported sensory neuropathy symptoms using the EORTC QLQ-CIPN20 sensory subscale. Secondary objectives include changes in overall neuropathy symptoms, physician-assessed neuropathy grade, quality of life, and safety. Exploratory assessments include nerve conduction findings and inflammatory biomarkers. The study aims to enroll approximately 43 patients and will provide early evidence on whether papaverine may be a useful treatment option for patients with refractory paclitaxel-induced CIPN.",[26,27,28],"Chemotherapy-Induced Peripheral Neuropathy","Refractory Chemotherapy-Induced Peripheral Neuropathy","Paclitaxel-Induced Peripheral Neuropathy","NOT_YET_RECRUITING","2026-05-05",{"date":32,"type":33},"2026-05-07","ACTUAL",{"date":35,"type":20},"2026-05-01",{"date":37,"type":20},"2027-05-01",{"name":39,"class":40},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":49,"minAge":16,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100631752","surgical-glove-compression-to-prevent-paclitaxel-neuropathy-100631752","NCT07504770","Surgical Glove Compression to Prevent Paclitaxel Neuropathy","Comparison of Surgical Glove Compressions as a Prophylactic Method to Prevent Paclitaxel-induced Peripheral Neuropathy: Randomized Controlled Trial","Surgical Glove","Inclusion Criteria:\n\n* Patients aged between 18 and 80 years\n* Diagnosed with Stage II-III breast cancer\n* No distant metastasis\n* Planned to receive adjuvant or neoadjuvant paclitaxel for at least 12 weeks\n* Willing and able to provide informed consent\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 Karnofsky ≥ 60%)\n\nExclusion Criteria:\n\n* Recurrent breast cancer\n* Prior treatment associated with neuropathy (e.g., taxanes, platinum-based chemotherapy, anti-tubulin or proteasome inhibitors)","FEMALE","80 Years",{"count":52,"type":20},84,[23],"This study aims to evaluate the effect of surgical glove compression as a prophylactic method to prevent paclitaxel-induced peripheral neuropathy. Participants will be randomly assigned to two groups: one receiving standard care, and the other receiving prophylactic surgical glove compression. The study will compare the development, severity of neuropathy in the hands and fingers, and its impact on quality of life.",[28,56,47],"Breast Cancer",[47,28,56],"2026-04-14",{"date":60,"type":33},"2026-04-17",{"date":62,"type":20},"2026-03-26",{"date":64,"type":20},"2027-03-26",{"name":66,"class":40},"Necmettin Erbakan University",1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":49,"minAge":16,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":21,"phases":76,"briefSummary":77,"conditions":78,"keywords":82,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":67},"100590237","the-effect-of-cold-salt-water-foot-bath-on-the-development-of-chemotherapy-induced-peripheral-neuropathy-100590237","NCT06964802","The Effect of Cold Salt Water Foot Bath on the Development Of Chemotherapy-Induced Peripheral Neuropathy","Inclusion Criteria:\n\n* Women aged 18 and over.\n* Conscious\n* Speaking and understanding Turkish\n* The diagnosis was breast cancer\n* Those who will receive paclitaxel chemotherapy\n* These are patients who answered 'no' to the 'A' section of the CIPNAT scale\n\nExclusion Criteria:\n\n* Responding to the vibration test (if the practitioner does not feel the vibration when the patient says they feel the vibration, it means that neuropathy is present)\n* Feeling pressure in one or none of the three areas on the plantar surface of the foot according to the monofilament test\n* Previous chemotherapy-associated peripheral neuropathy\n* Diagnosed with diabetes\n* Open wounds or skin ulcers on the foot\n* With peripheral and central nervous system disease\n* Peripheral vascular disease,\n* Patients with bone or soft tissue metastases",{"count":75,"type":20},30,[23],"This prospective, randomised, controlled study was designed to evaluate the effectiveness of salt and unsalted cold water foot baths in preventing chemotherapy-induced peripheral neuropathy (CIPN) in patients receiving paclitaxel. The study's sub-objectives were to minimise the development of CIPN, reduce its severity and incidence of symptoms, and minimise its impact on daily life and activities.\n\nHypothesis(es):\n\nH1: Salt cold water foot bath affects the development of chemotherapy-induced peripheral neuropathy.\n\nH2: There is an effect of unsalted cold water foot bath on the development of chemotherapy-induced peripheral neuropathy.\n\nH3: The effects of salt and unsalted cold water foot baths on the development of chemotherapy-induced peripheral neuropathy.\n\nH4: Salt and unsalted cold water foot baths are more effective than standard clinical care in the development of chemotherapy-induced peripheral neuropathy.\n\nResearchers will compare the salt cold water with the unsalted cold water, unsalted cold water and control group to determine whether the salt cold water has an effect on CIPN.\n\nThe experimental group and active comparator participants will continue the application for 12 cycles (12 weeks) of paclitaxel. The application will be applied by researcher Tuba Eryiğit. In addition, before each application for 12 weeks, the severity of CIPN, its effect on daily life and grade will be evaluated.\n\nThe control group will continue clinical routine care applications for 12 cycles (12 weeks). In addition, the severity of CIPN, its effect on daily life and grade will be evaluated before each treatment in the same way as the experimental groups.",[79,80,81],"Breast Cancer Patients","Chemotherapy Induced Peripheral Neuropathy (CIPN)","Paclitaxel-induced Peripheral Neuropathy",[26,83,84,56,85],"Cold Salt Water","Foot Bath","Paclitaxel","RECRUITING","2026-04-13",{"date":89,"type":33},"2026-04-16",{"date":91,"type":33},"2025-06-01",{"date":93,"type":20},"2026-07-01",{"name":95,"class":40},"Tuba Eryiğit",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":49,"minAge":16,"maxAge":17,"enrollmentInfo":103,"targetDuration":4,"studyType":21,"phases":105,"briefSummary":108,"conditions":109,"keywords":111,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":67},"100624479","phase-2-efficacy-and-safety-of-hyperbaric-oxygen-therapy-in-improving-nab-paclitaxel-induced-peripheral-neuropathy-100624479","NCT07410169","Efficacy and Safety of Hyperbaric Oxygen Therapy in Improving Nab-paclitaxel-Induced Peripheral Neuropathy","Efficacy and Safety of Hyperbaric Oxygen Therapy in Improving Nab-paclitaxel-Induced Peripheral Neuropathy: A Randomized Clinical Trial","Inclusion Criteria:\n\n1. aged ≥ 18 years and ≤ 75 years, female\n2. early-stage breast cancer or locally advanced breast cancer\n3. Patients who have completed adjuvant or neoadjuvant chemotherapy with nab-paclitaxel\n4. The patient developed nab-paclitaxel induced peripheral neuropathy (Nab-PIPN), as defined by meeting any of the following criteria: Patient Neurotoxicity Questionnaire (PNQ) score ≥ Grade B, NCI-CTCAE (sensory and motor neuropathy) grade ≥ 1, or neuropathic pain score ≥ 4\u002F10.\n5. The patient voluntarily participated in this study, provided written informed consent, and agreed to cooperate with follow-up assessments.\n\nExclusion Criteria:\n\n1. Patients who have previously taken drugs that may affect the evaluation of Nab-PIPN symptoms, such as duloxetine, venlafaxine, gabapentin, pregabalin, and amitriptyline.\n2. Patients with any other pathological conditions or diseases that could affect Nab-PIPN assessment, including alcoholic peripheral neuropathy, uremic peripheral neuropathy, diabetic peripheral neuropathy, thiamine deficiency-related peripheral neuropathy, and chronic axonal peripheral neuropathy of unknown etiology.\n3. Patients who have contraindications for hyperbaric oxygen therapy, including pulmonary disorders (severe chronic obstructive pulmonary disease, bullous lung disease, acute or chronic pulmonary infection, uncontrolled asthma, untreated pneumothorax), history of previous middle ear surgery, middle ear diseases (eustachian tube dysfunction, recurrent vertigo), and ocular conditions (retinal detachment).\n4. Patients with any disease history that may affect compliance, including severe mental disorders, cognitive impairment, substance abuse or addiction.\n5. Karnofsky Performance Status score \\\u003C 80\n6. Patients with any other conditions that the investigator deems unsuitable for participation in the study.",{"count":104,"type":20},160,[106,107],"PHASE2","PHASE3","The goal of this research is to assess whether hyperbaric oxygen therapy can alleviate the symptoms of Nab-paclitaxel-induced peripheral neuropathy and improve patient-reported quality of life.",[56,110,81],"CIPN - Chemotherapy-Induced Peripheral Neuropathy",[56,112,113],"paclitaxel-Induced Peripheral Neuropathy","Hyperbaric Oxygen Therapy","2026-02-07",{"date":116,"type":33},"2026-02-13",{"date":118,"type":20},"2026-01-31",{"date":120,"type":20},"2027-12-31",{"name":122,"class":40},"Guangdong Provincial People's Hospital",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":21,"phases":132,"briefSummary":133,"conditions":134,"keywords":135,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":67},"100574768","efficacy-of-surgical-glove-compression-therapy-as-a-prevention-of-paclitaxel-induced-peripheral-neuropathy-100574768","NCT06763575","Efficacy of Surgical Glove-Compression Therapy As a Prevention of Paclitaxel-Induced Peripheral Neuropathy","Efficacy of Surgical Glove-Compression Therapy As a Prevention of Paclitaxel-Induced Peripheral Neuropathy: Randomized Controlled Trial","Inclusion Criteria:\n\n* Signed Informed Consent Form\n* Age 18 years or older at the time of signing Informed Consent Form\n* Patients with any pathological diagnosis of solid tumor, such as breast cancer or lung cancer\n* Patients scheduled to be receiving intravenous paclitaxel or paclitaxel-based regimen every 3 weeks\n\nExclusion Criteria:\n\n* Patients whose received chemotherapeutic agents that could cause neuropathy, e.g. taxane-based or platinum-based chemotherapy and anti-microtubule\n* History of neuropathy\n* History of carpal tunnel syndrome\n* History of allergic reactions to latex or gloves\n* Patients receiving treatments that may treat neuropathy, e.g. amitriptyline, gabapentin, Acetyl L-Carnitine and Ganglioside-monosialic acid, acupuncture, cryotherapy or exercise therapy\n* History of Raynaud phenomenon\n* History of wounds or large scars on hands\n* Pregnancy or breastfeeding\n* History of poorly controlled diabetes; HbA1c\\>6.5",{"count":131,"type":20},36,[23],"The aim of this randomized controlled trial (RCT) is to compare the incidence of paclitaxel-induced grade 2 or higher sensory peripheral neuropathy, evaluated using the CTCAE version 5.0, between patients receiving surgical glove-compression therapy (SGCT) and those in the control group.\n\nThe main question is whether SGCT is effective in preventing paclitaxel-induced sensory peripheral neuropathy.\n\n* Intervention group: receive SGCT.\n* Control group: receive non-compressive plastic gloves.",[81],[85,136,137],"Surgical Glove-Compression Therapy","Peripheral Neuropathy","2025-01-02",{"date":140,"type":33},"2025-01-08",{"date":142,"type":20},"2025-01-01",{"date":144,"type":20},"2026-06-01",{"name":146,"class":147},"Department of Medical Services Ministry of Public Health of Thailand","OTHER_GOV"]